Using data gathered through analysis of the genetic makeup of a tumor, a new study could lead to tailored treatment for those battling breast cancer. This groundbreaking study would reclassify the disease into 10 new categories or subtypes, giving doctors information to make better treatment recommendations and helping patients avoid unnecessary treatment. This is exciting news for the PBCC and all those we serve, as it could revolutionize treatment of breast cancer and give many women better outcomes with fewer side effects.
The Cambridge study, which is the largest genetic study of breast cancer to date, has been heralded as a step toward individualizing treatment for patients, allowing many to avoid treatment that would be less likely to benefit them. The next step in the process is establishing clinical trials. Within three to five years, doctors may be able to start development of more accurate diagnostic tests.
The PBCC is impressed with the results of the study and encouraged that tailored, more individualized breast cancer therapy may become a reality but, of course, clinical trials must be conducted first.